首页> 外文期刊>Peptides: An International Journal >Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo.
【24h】

Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo.

机译:对应于组织因子途径抑制剂的C末端的肽在体内抑制肾小球膜细胞的增殖和活化。

获取原文
获取原文并翻译 | 示例
           

摘要

Mesangial cells (MsCs) are one of the resident cell types in the glomerulus and are important with respect to its function and structure. The activation and proliferation of MsCs occur in several types of glomerulonephritis, particularly proliferative glomerulonephritis, producing a series of protein factors and matrix components that impair the normal structure and function of the glomerulus. To inhibit proliferation or induction of apoptosis is considered to be one mechanism that can be used to treat these diseases. In previous studies, we found that the tissue factor pathway inhibitor (TFPI) induces the apoptosis of cultured rat MsCs. Here, we expressed a series of TFPI fragments as fusion proteins to maltose binding protein (MBP-TFPI(162-188), MBP-TFPI(187-241), MBP-TFPI(240-276), MBP-TFPI(162-241), MBP-TFPI(187-276) and MBP-TFPI(162-276)) and applied them to cultured rat mesangial cells. The C terminus of TFPI, a peptide corresponding to residues 240-276 of TFPI, was confirmed to induce apoptosis of MsCs in vitro. To observe the effect of this peptide on MsCs in vivo, we performed intramuscular gene transfer treatment on a rat model of proliferative glomerulonephritis with a plasmid containing the gene for the C terminus of TFPI. This revealed that the C terminus of TFPI exhibited suppressive effects on the activation and proliferation of MsCs and, thereby, improved renal function. Our data indicate that the C terminus of TFPI could be used in the treatment of proliferative glomerulonephritis.
机译:肾小球系膜细胞(MsCs)是肾小球中的一种常驻细胞,在其功能和结构方面很重要。 MsCs的激活和增殖发生在几种类型的肾小球肾炎中,尤其是增殖性肾小球肾炎,产生一系列损害肾小球正常结构和功能的蛋白质因子和基质成分。抑制增殖或诱导凋亡被认为是可用于治疗这些疾病的一种机制。在以前的研究中,我们发现组织因子途径抑制剂(TFPI)诱导培养的大鼠MsCs的凋亡。在这里,我们表达了一系列TFPI片段作为麦芽糖结合蛋白的融合蛋白(MBP-TFPI(162-188),MBP-TFPI(187-241),MBP-TFPI(240-276),MBP-TFPI(162- 241),MBP-TFPI(187-276)和MBP-TFPI(162-276)),并将它们应用于培养的大鼠系膜细胞。 TFPI的C端(一种与TFPI的残基240-276相对应的肽)已被证实在体外诱导MsCs凋亡。为了观察该肽对体内MsCs的作用,我们用含有TFPI C末端基因的质粒对增生性肾小球肾炎大鼠模型进行了肌内基因转移治疗。这表明TFPI的C末端对MsC的活化和增殖表现出抑制作用,从而改善了肾功能。我们的数据表明,TFPI的C末端可用于治疗增生性肾小球肾炎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号